05:53 AM EDT, 10/20/2025 (MT Newswires) -- Incyte ( INCY ) said Monday that data from clinical testing of the therapies INCA33890 for patients with microsatellite stable colorectal cancer and its INCB161734 for patients with specifically pancreatic ductal adenocarcinoma "support continued clinical development" and show "favorable safety profiles."

A phase 1 trial of INCA33890 Phase 1 trial of 260 patients with advanced or metastatic solid tumors who experienced disease progression after receiving standard therapies or were intolerant to, ineligible for, or declined standard treatments "demonstrated a manageable safety profile,' the company said.

Among 105 patients with metastatic microsatellite stable colorectal cancer 15.2% achieved an objective response rate and a median duration of therapy of 7.3 months, the company said.

INCB161734 also showed a manageable safety profile across all 136 treated patients while pancreatic ductal adenocarcinoma patients showed objective response rates of objective response rates of 20% and 34% depending on the dosage, the company said.